Singapore, July 25 -- India's Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has launched Nepexto(R), a biosimilar to the reference product Enbrel(R) (Etanercept), in Australia.

Nepexto(R) will be promoted by GenericHealth, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-countermedicines, to expand access to patients in Australia.

Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis,juvenile idiopathic arthritisandpsoriatic arthritis,plaque psoriasisandankylosing spondylitis.

Since receiving EU marketing authorisation in 2020, Nep...